Eskata is owned by Aclaris.
Eskata contains Hydrogen Peroxide.
Eskata has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Eskata are:
Eskata was authorised for market use on 14 December, 2017.
Eskata is available in solution;topical dosage forms.
Eskata can be used as treatment of seborrheic keratoses that are raised.
The generics of Eskata are possible to be released after 04 July, 2035.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7381427 | ACLARIS | Seborrheic keratosis treatment |
Jun, 2022
(8 months ago) | |
US10098910 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(12 years from now) | |
US9980983 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(12 years from now) | |
US10493103 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(12 years from now) | |
US10729720 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(12 years from now) | |
US9675639 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Jul, 2035
(12 years from now) |
Drugs and Companies using HYDROGEN PEROXIDE ingredient
Market Authorisation Date: 14 December, 2017
Treatment: Treatment of seborrheic keratoses that are raised
Dosage: SOLUTION;TOPICAL
14
United States
3
Australia
2
China
2
Brazil
2
Canada
2
Singapore
2
Mexico
2
Japan
2
European Union
1
Austria
1
Korea, Republic of
1
Denmark
1
Russia
1
Spain
1
Germany
1
Israel
1
New Zealand
1
Portugal
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic